Get All Access for FREE.
Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,
and a whole lot more…

Build Wealth

{{::item.ticker}} • {{::item.company_name}} No Results
login

$SYK (Stryker Corporation)

$SYK {{ '2015-06-23T19:57:52+0000' | timeago}} • SEC

$SYK 1Q15 10-Q: Consolidated net sales increased 3.2%. Net sales grew 7.1% as a result of increased unit volume and changes in product mix and 1.9% due to acquisitions, and were unfavorably impacted by 4.2% due to ForEx rates and 1.6% due to changes in price. Excluding the impact of acquisitions, net sales increased by 5.6% in constant currency.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$GE {{ '2017-06-14T12:04:29+0000' | timeago}} • Announcement

$GE's GE Additive and $SYK have entered a partnership agreement to support $SYK's growth in additive manufacturing. The agreement covers new additive machines, materials and services for $SYK's global supply chain operations.

$SYK {{ '2017-05-08T16:05:41+0000' | timeago}} • Announcement

$SYK said its subsidiary Howmedica Osteonics will move forward with the 2016 Settlement Program that provides for compensation to additional eligible U.S. patients who had surgery to replace their Rejuvenate Modular-Neck hip stem and/or ABG II Modular-Neck hip stem, known as a revision surgery, prior to Dec. 19, 2016.

$SYK {{ '2017-05-08T16:04:06+0000' | timeago}} • Announcement

$SYK said its subsidiary Howmedica Osteonics has informed the courts in the New Jersey Multicounty and Federal Multidistrict litigations that 95% of additional registered eligible patients have enrolled in the Settlement Program under the Master Settlement Agreement announced in December 2016.

$SYK {{ '2017-05-03T12:53:59+0000' | timeago}} • Announcement

$SYK's BoD declared a quarterly dividend of $0.425 per share, payable on July 31, 2017 to shareholders of record on June 30, 2017. This represents an increase of 12% versus the prior year and unchanged from the previous quarter.

$SYK {{ '2017-04-25T21:46:05+0000' | timeago}} • Webcast

$SYK said spine is an important part of its growth strategy. The company plans to launch a number of new products over the course of 2017 which are expected to accelerate growth. $SYK also plans to bring a couple of products back on the market and these are starting to take hold. $SYK expects the spine business to improve in 2017.

$SYK {{ '2017-04-25T21:30:27+0000' | timeago}} • Webcast

$SYK is positive on the pace of the MAKO system upgrades. The company started doing the upgrades in 4Q16 and they are continuing to accelerate sequentially. $SYK believes the vast majority of the robots in the field will get upgraded and this process will continue through 2018. The company expects these upgrades to continue to build.

$SYK {{ '2017-04-25T20:36:17+0000' | timeago}} • Announcement

For FY17, $SYK anticipates organic sales growth to be in the range of 5.5-6.5%. Adjusted net EPS is expected to be in the range of $6.35-6.45.

$SYK {{ '2017-04-25T20:32:41+0000' | timeago}} • Announcement

Medical technology company $SYK reported 10.4% increase in its 1Q17 earnings, helped by increased revenue growth. Net earnings rose to $444MM from $402MM during 1Q16. Diluted EPS rose 9.3% to $1.17 from $1.07 in prior year quarter. Net sales rose 18.4% YoY to $2.96Bil. Excluding items, $SYK earned $1.48 per share, up 19.4%.

$SYK {{ '2017-02-08T15:32:03+0000' | timeago}} • Announcement

$SYK BoD declared a quarterly dividend of $0.425 per share payable on April 28, 2017 to shareholders of record on March 31, 2017. This represents 12% increase versus the prior year.

$SYK {{ '2017-01-24T22:02:57+0000' | timeago}} • Webcast

$SYK's Orthopaedics segment net sales of $1.2Bil increased 5.3% in 4Q16 versus 4Q15. MedSurg net sales of $1.4Bil increased 31.1% in 4Q16. Neurotechnology and Spine net sales of $526MM increased 8.7% in 4Q16.

$SYK {{ '2017-01-24T21:58:33+0000' | timeago}} • Webcast

For 4Q16, $SYK’s US sales demonstrated strong momentum with organic growth of 6.3%, reflecting solid performances across the portfolio. International sales grew 7.7% organically, highlighted by gains in Europe, Canada and Australia, and a return to growth in China.

$SYK {{ '2017-01-24T21:54:14+0000' | timeago}} • Webcast

$SYK achieved success with Mako as it installed a total of 32 robots globally in 4Q16, of which 24 were in the US. For full-year 2016, Mako installations totaled 86, an increase of 14 YoverY, which brings the total number of robots globally to 381 with 333 in the US.

$SYK {{ '2017-01-24T21:36:17+0000' | timeago}} • Announcement

$SYK expects 2017 organic sales growth to be 5.5-6.5%. Adjusted diluted EPS is expected to be $1.40-1.45 in 1Q17 and $6.35-6.45 in the full year 2017.

$SYK {{ '2017-01-24T21:30:30+0000' | timeago}} • Announcement

Medical technology company $SYK reported a decrease in 4Q16 earnings. Net earnings decreased 2.3% to $510MM and diluted EPS decreased 2.9% to $1.34 compared to 4Q15. Consolidated net sales of $3.2Bil increased 16.2% in 4Q16 versus last year.

$SYK {{ '2017-01-11T12:14:46+0000' | timeago}} • Announcement

$SYK reported preliminary net sales results for 4Q16. Net sales rose 16.3% to $3.2Bil, helped by the acquisitions of Sage Products LLC and Physio-Control International. The company expects 2016 adjusted diluted EPS to be at the high end of the previously stated outlook of $5.75-5.80, an increase of 12.3-13.3% over 2015.

$SYK {{ '2016-12-07T19:51:18+0000' | timeago}} • Announcement

$SYK's BoD declared quarterly dividend of $0.425 per share. The dividend is payable on Jan. 31, 2017 to shareholders of record on Dec. 30, 2016. This represents an increase of 12% versus the prior year and the previous quarter.

$SYK {{ '2016-11-14T16:03:19+0000' | timeago}} • Announcement

$SYK announced multi-year collaboration with Indo UK Institute of Health's (IUIH) Medicity Program to serve as preferred partner in orthopaedic areas of hip, knee and trauma products and services. $SYK and IUIH's new relationship will provide greater access to affordable primary joint replacements and other healthcare services to patients in India.

$SYK {{ '2016-10-27T23:32:47+0000' | timeago}} • Webcast

Geographically, $SYK's 3Q16 sales were balanced with a 6% increase in the US and a 6.7% gain in international, driven by good momentum in Europe and emerging markets. In 4Q16, the company expects its China business to show some improvement as prior year comparables ease.